WO2008103849A3 - Methods and compounds for lymphoma cell detection and isolation - Google Patents
Methods and compounds for lymphoma cell detection and isolation Download PDFInfo
- Publication number
- WO2008103849A3 WO2008103849A3 PCT/US2008/054613 US2008054613W WO2008103849A3 WO 2008103849 A3 WO2008103849 A3 WO 2008103849A3 US 2008054613 W US2008054613 W US 2008054613W WO 2008103849 A3 WO2008103849 A3 WO 2008103849A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ror
- isolation
- compounds
- methods
- sera
- Prior art date
Links
- 206010025323 Lymphomas Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 238000002955 isolation Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000043366 Wnt-5a Human genes 0.000 abstract 1
- 108700020483 Wnt-5a Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Abstract
Compositions comprising a purified and/or isolated antibody, humanized antibodies, precipitates and anti-sera that specifically bind to or are otherwise directed against ROR-1 protein. The compositions may be used for detecting ROR-1 in a sample from a subject that is suspected or known to contain cancer cells. The ROR-1 antibodies are especially useful in identifying and treating lymphomas and ademocarcinomas. Vaccines and related methods for protecting a subject against diseases that involve expression of ROR-1 are also provided, as are human anti-sera effective in abrogating interactions between Wnt5a protein and ROR-1 that contribute to the survival of certain cancer cells, such as CLL cells.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/545,731 US8212009B2 (en) | 2005-10-28 | 2009-08-21 | Methods and compounds for lymphoma cell detection and isolation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/709,917 US20070207510A1 (en) | 2005-10-28 | 2007-02-21 | Methods and compounds for lymphoma cell detection and isolation |
US11/709,917 | 2007-02-21 | ||
US97181807P | 2007-09-12 | 2007-09-12 | |
US60/971,818 | 2007-09-12 |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/042689 Continuation-In-Part WO2007051077A2 (en) | 2005-10-28 | 2006-10-30 | Methods and compounds for lymphoma cell detection and isolation |
US11/709,917 Continuation US20070207510A1 (en) | 2005-10-28 | 2007-02-21 | Methods and compounds for lymphoma cell detection and isolation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/545,731 Continuation-In-Part US8212009B2 (en) | 2005-10-28 | 2009-08-21 | Methods and compounds for lymphoma cell detection and isolation |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2008103849A2 WO2008103849A2 (en) | 2008-08-28 |
WO2008103849A3 true WO2008103849A3 (en) | 2008-10-23 |
WO2008103849A4 WO2008103849A4 (en) | 2009-01-22 |
Family
ID=39710749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/054613 WO2008103849A2 (en) | 2005-10-28 | 2008-02-21 | Methods and compounds for lymphoma cell detection and isolation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008103849A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9523695B2 (en) | 2011-01-14 | 2016-12-20 | The Regents Of The University Of California | Therapeutic antibodies against ROR-1 protein and methods for use of same |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9316646B2 (en) | 2009-04-23 | 2016-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ROR1 antibodies |
US8877199B2 (en) | 2009-05-15 | 2014-11-04 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | B cell surface reactive antibodies |
EP2496605A1 (en) * | 2009-11-02 | 2012-09-12 | Oxford Biotherapeutics Ltd. | Ror1 as therapeutic and diagnostic target |
GB2476293A (en) * | 2009-12-18 | 2011-06-22 | Biolnvent Internat Ab | Therapeutic inhibition of ROR-1 |
EP2513146B1 (en) | 2009-12-18 | 2017-05-03 | Kancera AB | Antibodies against ror1 capable of inducing cell death of cll |
WO2011159847A2 (en) | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof |
WO2012045085A1 (en) * | 2010-10-01 | 2012-04-05 | Oxford Biotherapeutics Ltd. | Anti-rori antibodies |
CA2881966C (en) | 2012-08-24 | 2020-10-06 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
ES2850325T3 (en) | 2014-10-09 | 2021-08-27 | Engmab Sarl | Bispecific antibodies against CD3epsilon and ROR1 |
EA201891066A1 (en) | 2015-10-30 | 2018-10-31 | ЭнБиИ-ТЕРАПЬЮТИКС АГ | ANTIBODIES TO ROR1 |
AU2017210327A1 (en) | 2016-01-20 | 2018-08-09 | Nbe-Therapeutics Ag | ROR1 antibody compositions and related methods |
CA3029003A1 (en) | 2016-06-27 | 2018-01-04 | The Regents Of The University Of California | Cancer treatment combinations |
EP3484516A4 (en) | 2016-07-14 | 2020-03-18 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
SG11202000846WA (en) | 2017-08-07 | 2020-02-27 | Nbe Therapeutics Ag | Anthracycline-based antibody drug conjugates having high in vivo tolerability |
-
2008
- 2008-02-21 WO PCT/US2008/054613 patent/WO2008103849A2/en active Application Filing
Non-Patent Citations (5)
Title |
---|
BASKAR S. ET AL.: "Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia", CLINICAL CANCER RESEARCH, vol. 14, no. 2, 15 January 2008 (2008-01-15), pages 396 - 404, XP009135221, DOI: doi:10.1158/1078-0432.CCR-07-1823 * |
FUKUDA T. ET AL.: "Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE, USA, vol. 105, no. 8, 19 February 2008 (2008-02-19), pages 3047 - 3052, XP009135222, DOI: doi:10.1073/pnas.0712148105 * |
KATOH M.: "WNT/PCP signaling pathway and human cancer (review)", ONCOLOGY REPORTS, vol. 14, no. 6, December 2005 (2005-12-01), pages 1583 - 1588, XP009104214 * |
MASIAKOWSKI P. AND CARROLL R.D.: "A novel family of cell surface receptors with tyrosine kinase-like domain", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 36, 25 December 1992 (1992-12-25), pages 26181 - 26190, XP002266720 * |
PAGANONI S. AND FERREIRA A.: "Expression and subcellular localization of Ror tyrosine kinase receptors are developmentially regulated in cultured hippocampal neurons", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 73, 15 August 2003 (2003-08-15), pages 429 - 440 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9523695B2 (en) | 2011-01-14 | 2016-12-20 | The Regents Of The University Of California | Therapeutic antibodies against ROR-1 protein and methods for use of same |
Also Published As
Publication number | Publication date |
---|---|
WO2008103849A4 (en) | 2009-01-22 |
WO2008103849A2 (en) | 2008-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008103849A3 (en) | Methods and compounds for lymphoma cell detection and isolation | |
WO2007051077A3 (en) | Methods and compounds for lymphoma cell detection and isolation | |
NZ629273A (en) | Compositions and methods for the treatment of infections and tumors | |
WO2010063011A3 (en) | Methods for the treatment of infections and tumors | |
WO2005097185A3 (en) | Irta-5 antibodies and their uses | |
WO2012097313A3 (en) | Therapeutic antibodies against ror-1 protein and methods for use of same | |
WO2008076560A3 (en) | Human monoclonal antibodies to btla and methods of use | |
BRPI0613279A8 (en) | MANOCLONAL ANTIBODY ISOLATED, IMMUNOCONJUGATE, NUCLLEIC ACID MOLECULE ISOLATED, EXPRESSION VECTOR, HOST CELL, METHOD FOR PREPARING AN ANTI-CD19 ANTIBODY, METHOD FOR INHIBIT THE GROWTH OF TUMOR CELLS EXPRESSING CD19, AND METHOD FOR DEPLETING B CELLS IN AN INDIVIDUAL | |
WO2010129609A3 (en) | Antibodies and methods of use thereof | |
EP1855719A4 (en) | Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus | |
WO2007133822A8 (en) | Gitr antibodies for the treatment of cancer | |
BRPI0618399A2 (en) | isolated antigen binding region that is specific for cd38, isolated antibody or a functional fragment thereof that is specific for cd38, isolated antibody or a functional fragment thereof, isolated immunoglobulin, heavy chain variable of an isolated antigen binding region, variable light chain from an isolated antigen binding region, isolated nucleic acid sequence, nucleic acid sequence encoding a variable heavy chain from an isolated antigen binding region, nucleic acid sequence, vector, isolated cell, pharmaceutical composition, use of the pharmaceutical composition, method of inducing specific death of cd38-expressing tumor cells, method of detecting specific death of cd38-expressing tumor cells, method of detecting the presence of cd38 in a minipore source tissue or cell , cd38 detection method in a cd3-expressing erythrocyte 8 and diagnostic composition | |
SG163554A1 (en) | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) | |
BRPI0613382A8 (en) | isolated antibodies, monoclonal antibody, hybridoma cell, identification method, cell growth inhibition method, therapeutic treatment method, protein presence determination method, tumor presence diagnosis methods | |
EP3530736A3 (en) | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics | |
WO2008019376A3 (en) | Compositions and methods using anti-cs1 antibodies to treat multiple myeloma | |
WO2006116181A3 (en) | Regulatory t cell mediator proteins and uses thereof | |
NZ593289A (en) | Anti-neuropilin-1 antibodies for treating angiogenesis | |
MX2009006275A (en) | Human antibodies that bind cd19 and uses thereof. | |
WO2010009124A3 (en) | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds | |
WO2006124641A3 (en) | Anti-mesothelin antibodies useful for immunological assays | |
EA201070636A1 (en) | INHIBITION OF THE PROTECTOR PROTEIN, STIMULATING MACROPHAGE (RON), AND METHODS OF ITS TREATMENT | |
SG155931A1 (en) | Wnt proteins and detection and treatment of cancer | |
EA032189B9 (en) | Isolated human monoclonal antibodies against tissue factor pathway inhibitor (tfpi) and pharmaceutical composition comprising same | |
UA105760C2 (en) | Bst2 antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08730419 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08730419 Country of ref document: EP Kind code of ref document: A2 |